What's Happening?
May Health, a medical device company focused on treating polycystic ovary syndrome (PCOS)-related infertility, has raised $11.7 million in funding. The investment round included participation from existing investors such as Sofinnova Partners, Trill Impact,
and Bpifrance, along with new investor Nexpring Health. The funds will be used to complete the U.S. Investigational Device Exemption (IDE) trial, REBALANCE, and support the launch of the Anavi System in Europe. The Anavi System is designed to restore ovulation in women with PCOS-related infertility who do not respond to first-line therapies. PCOS affects 10-13% of women worldwide and is a leading cause of female infertility.
Why It's Important?
The funding is significant as it supports the development of new treatment options for women with PCOS-related infertility, a condition that affects millions globally. By advancing the REBALANCE trial, May Health aims to provide a novel solution for women who struggle with infertility due to PCOS. This development could reshape the treatment paradigm for PCOS, offering hope to those who have not found success with existing therapies. The involvement of Nexpring Health, a leader in assisted reproductive technologies, underscores the potential impact of May Health's innovations on fertility care.
What's Next?
May Health plans to continue enrolling participants in the REBALANCE trial across more than 15 fertility centers in the United States. The trial's success could lead to FDA marketing authorization, allowing the Anavi System to be available in the U.S. market. Additionally, the company is preparing for the European launch of the Anavi System, which has already received CE Mark certification. These steps are crucial for expanding treatment options and improving outcomes for women with PCOS-related infertility.
